Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 941-948

  Tanaka, Tetsuji ^a   Bai, Tao ^a   Yukawa, Kazunori ^a   Utsunomiya, Tomoko ^a   Umesaki, Naohiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CD40; Cervical cancer; Cyclophosphamide; Drug resistance; Radioresistance

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4-HYDROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; BLEOMYCIN; CD40 ANTIGEN; CD40 LIGAND; CD59 ANTIGEN; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE;

ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; RADIATION DOSE; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANTIGENS, CD29; ANTIGENS, CD40; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; INTEGRIN ALPHA1; INTEGRIN ALPHA2; INTEGRIN ALPHA3; INTEGRIN ALPHA4; INTEGRIN ALPHA5; INTEGRIN ALPHA6; RADIATION TOLERANCE; UTERINE CERVICAL NEOPLASMS;

EID: 33644830137     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.941     Document Type: Article

References (14)

1. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K and Izumi R: Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol 95: 127-132, 2004. (Pubitemid 39286287)
2. Lancillotti F, Giandomenico V, Affabris E, Fiorucci G, Romeo G and Rossi GB: Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 55: 3158-3164, 1995.
3. Lefkovits I: Limiting dilution analysis. In: Immunological Methods. Academic Press, pp355-370, 1979.
4. Chang L, Tanaka T, Umesaki N and Ogita S: Differential apoptotic susceptibility to anti-Fas IgM and anticancer drugs in a human endometrial adenocarcinoma cell line HHUA on laminin and type I collagen. Osaka City Med J 44: 173-180, 1998.
5. Hayashida K, Shimaoka Y, Ochi T and Lipsky PE: Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-XL expression by B cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 164: 1110-1116, 2000. (Pubitemid 30043741)
6. Walker A, Taylor ST, Hickman JA and Dive C: Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase colonogenicity of drug-treated human B lymphoma cells. Cancer Res 57: 1939-1945, 1997. (Pubitemid 27209725)
7. Voorzanger-Rousselot N, Favrot M and Blay JY: Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 92: 3381-3387, 1998. (Pubitemid 28492348)
8. Kitada S, Zapata JM, Andreeff M and Reed JC: Bryostatin and CD40-ligand enhhannce apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukemia. Br J Haemmatol 1066: 995-1004, 1999. (Pubitemid 29463014)
9. Taylor ST, Hickman JA and Dive C: Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 92: 18-23, 2000. (Pubitemid 30082224)
10. Stumm S, Meyer A, Lindner M, Bastert G, Wallwiener D and Guckel B: Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 66: 101-111, 2004. (Pubitemid 38608376)
11. Voorzanger-Rousselot N and Blay JY: Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells, an autocrine anti-apoptotic role. Leuk Lymphoma 45: 1239-1245, 2004. (Pubitemid 38584909)
12. Lalmanach-Girard AC, Chiles TC, Parker DC and Rothstein TL: T cell-dependent induction of NF-kappa B in B cells. J Exp Med 177: 1215-1219, 1993.
13. Schauer SL, Wang Z, Sonenshein GE and Rothstein TL: Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescuee of WEHI231 early B cells from receptor mediated apoptosis through modulation of I kappa B proteins. J Immunol 155: 81-86, 1996. (Pubitemid 26190534)
14. Ottaiani A, Pisano C, De Chiara A, Barletta E, Ascierto AP, Botti G, Napolitano M, Apice G and Laffaioli RV: Expression of CD40 has no predictive value in soft tissue sarcomas. Anticancer Res 23: 1597-16004, 2003.